Literature DB >> 20126608

Medical management of lower urinary tract symptoms.

Eric E Laborde1, Kevin T McVary.   

Abstract

Lower urinary tract symptoms (LUTS) are a common complaint among aging men and are often caused by benign prostatic hyperplasia (BPH). A number of medical treatments for LUTS/BPH exist, such as alpha-blockers, 5alpha-reductase inhibitors, anticholinergics, phosphodiesterase type 5 (PDE5) inhibitors, and combination therapies. Agonist binding of the alpha(1A)-adrenergic receptor (AR), causing prostatic smooth muscle contraction, has been attributed to cause some LUTS. Therefore, medical therapy has aimed to block the alpha(1A)-AR and improve LUTS. Determining which therapy to choose must take into account individual patient factors as well as cost and patient choice.

Entities:  

Keywords:  5α-reductase inhibitors; Anticholinergics; Benign prostatic hyperplasia; Combination therapy; Lower urinary tract symptoms; Phosphodiesterase type 5 inhibitors; α-Blockers

Year:  2009        PMID： 20126608      PMCID： PMC2812890     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  34 in total

1.  Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.

Authors:  Yong Yang; Xiao-feng Zhao; Han-zhong Li; Wei Wang; Yong Zhang; He Xiao; Xin Zhang
Journal:  Chin Med J (Engl)       Date:  2007-03-05       Impact factor: 2.628

2.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Authors:  J D McConnell; R Bruskewitz; P Walsh; G Andriole; M Lieber; H L Holtgrewe; P Albertsen; C G Roehrborn; J C Nickel; D Z Wang; A M Taylor; J Waldstreicher
Journal:  N Engl J Med       Date:  1998-02-26       Impact factor: 91.245

Review 3.  Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence.

Authors:  Karl-Erik Andersson; Alan J Wein
Journal:  Pharmacol Rev       Date:  2004-12       Impact factor: 25.468

4.  The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes.

Authors:  A J Noble; R Chess-Williams; C Couldwell; K Furukawa; T Uchyiuma; C Korstanje; C R Chapple
Journal:  Br J Pharmacol       Date:  1997-01       Impact factor: 8.739

5.  Alpha1-adrenergic receptor subtypes in human detrusor.

Authors:  B J Malloy; D T Price; R R Price; A M Bienstock; M K Dole; B L Funk; X L Rudner; C D Richardson; C F Donatucci; D A Schwinn
Journal:  J Urol       Date:  1998-09       Impact factor: 7.450

6.  The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle.

Authors:  H Lepor; R Tang; E Shapiro
Journal:  Prostate       Date:  1993       Impact factor: 4.104

7.  Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.

Authors:  J D McConnell; J D Wilson; F W George; J Geller; F Pappas; E Stoner
Journal:  J Clin Endocrinol Metab       Date:  1992-03       Impact factor: 5.958

8.  A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing.

Authors:  C de Mey; M C Michel; J McEwen; T Moreland
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

Review 9.  Nitric oxide synthase and nitric oxide-mediated effects in lower urinary tract smooth muscles.

Authors:  K E Andersson; K Persson
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

10.  Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology.

Authors:  D T Price; R J Lefkowitz; M G Caron; D Berkowitz; D A Schwinn
Journal:  Mol Pharmacol       Date:  1994-02       Impact factor: 4.436
View more
  8 in total

1.  Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.

Authors:  Jill A Macoska; Kristen S Uchtmann; Glen E Leverson; Kevin T McVary; William A Ricke
Journal:  J Urol       Date:  2019-06-12       Impact factor: 7.450

Review 2.  Prostatic fibrosis, lower urinary tract symptoms, and BPH.

Authors:  Jose A Rodriguez-Nieves; Jill A Macoska
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

3.  Prostatic fibrosis is associated with lower urinary tract symptoms.

Authors:  Jinjin Ma; Mehrnaz Gharaee-Kermani; Lakshmi Kunju; John M Hollingsworth; Jeremy Adler; Ellen M Arruda; Jill A Macoska
Journal:  J Urol       Date:  2012-08-17       Impact factor: 7.450

Review 4.  Promising molecular targets and biomarkers for male BPH and LUTS.

Authors:  Mehrnaz Gharaee-Kermani; Jill A Macoska
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

5.  CXCL12/CXCR4 Axis Activation Mediates Prostate Myofibroblast Phenoconversion through Non-Canonical EGFR/MEK/ERK Signaling.

Authors:  José A Rodríguez-Nieves; Susan C Patalano; Diego Almanza; Mehrnaz Gharaee-Kermani; Jill A Macoska
Journal:  PLoS One       Date:  2016-07-19       Impact factor: 3.240

6.  The IL-4/IL-13 signaling axis promotes prostatic fibrosis.

Authors:  Quentin D'Arcy; Mehrnaz Gharaee-Kermani; Alisa Zhilin-Roth; Jill A Macoska
Journal:  PLoS One       Date:  2022-10-06       Impact factor: 3.752

7.  CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis.

Authors:  Mehrnaz Gharaee-Kermani; Sathish Kasina; Bethany B Moore; Dafydd Thomas; Rohit Mehra; Jill A Macoska
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

8.  Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.

Authors:  Smita Pattanaik; Ravimohan S Mavuduru; Arabind Panda; Joseph L Mathew; Mayank M Agarwal; Eu Chang Hwang; Jennifer A Lyon; Shrawan K Singh; Arup K Mandal
Journal:  Cochrane Database Syst Rev       Date:  2018-11-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.